Eye­ing an IPO, Ful­crum ex­ecs nail down an $80M round on the way to the clin­ic with their first gene-reg­u­lat­ing drug

In the lat­est sign that there’s more and more mon­ey chas­ing good sci­ence, Ful­crum Ther­a­peu­tics has grabbed an $80 mil­lion B round to back its …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.